Warneford is currently developing higher strength 1mg / 1ml oral solution. This is especially suitable for patients with chronic symptoms required higher dose which can be titrated easily with the oral solution.
Warneford is also developing a sustained release formulation to reduce dose intervals for patients taking a significant volume of medications.
Nalolax plus analgesic
Warneford is working with clinicians on the combination of Nalolax with commonly used opioids such as oxycodone, morphine and hydrocodone.